Tilray (TLRY – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Robert Moskow from TD Cowen maintained a Buy rating on the stock and has a $1.00 price target.
Robert Moskow has given his Buy rating due to a combination of factors, despite the challenges faced by Tilray. The company is undergoing a strategic realignment, focusing on optimizing its beer portfolio by right-sizing the brands acquired from AB InBev and Molson Coors. This effort is expected to streamline operations and enhance growth in core markets, such as Montauk in the New York metro area.
Furthermore, management anticipates stronger performance in the upcoming fiscal quarters, driven by seasonal growth in the beer segment and improved utilization of their new infused pre-roll and vape facility. Although the price target has been lowered to $1.00 per share, reflecting a more conservative valuation multiple due to market conditions, the long-term growth prospects and operational adjustments support the Buy rating.